NCT00218322View on ClinicalTrials.gov

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2006

Conditions
Attention Deficit Disorder With HyperactivitySubstance-Related Disorders
Interventions
DRUG

Atomoxetine hydrochloride

Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.

DRUG

Placebo

Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00218322 - Effectiveness of ATMX in Treating Adolescents With ADHD and SUD | Biotech Hunter | Biotech Hunter